Yusheng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yusheng Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Baocheng Xie
Department of Pharmacy, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People’s Hospital), China
2 shared publications - Chenhui Zhou
School of Nursing, Guangdong Medical University, Dongguan 523808, China
1 shared publication - Daohua Xu
Department of Pharmacology, Guangdong Medical University, Dongguan, China -
1 shared publication - Hou-Long Luo
Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
1 shared publication - Qinghui Wang
Department of Pharmacology, Guangdong Medical University, Dongguan 523808, China
1 shared publication W. Y. Weng
Department of Pharmacy, Guangdong Medical University, No. 1, Xincheng Dadao, Songshan Lake Science and Technology Industry Park, Dongguan, 523808, China
1 shared publication
Latest Publications
- 6 August 2018
- Published by Springer Nature in Osteoporosis International
- Vol. 29 (12) , 2639-2644
Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
Our network meta-analysis analyzed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on fracture risk. By combining data from randomized controlled trials, we found that GLP-1 RAs were associated with a decreased bone fracture risk, and exenatide is the best option agent with regard to the risk of fracture. This study is registered with PROSPERO (CRD42018094433).
- 6 August 2018
- Published by Springer Nature in Osteoporosis International
- Vol. 29 (12) , 2639-2644
Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials
Our network meta-analysis analyzed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on fracture risk. By combining data from randomized controlled trials, we found that GLP-1 RAs were associated with a decreased bone fracture risk, and exenatide is the best option agent with regard to the risk of fracture. This study is registered with PROSPERO (CRD42018094433).
- Open Access
- 24 May 2018
- Published by Wiley in Stem Cells International
- Vol. 2018, 1-12
Autologous Stem Cell Therapy in Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials
Objective. Critical limb ischemia (CLI) is the most dangerous stage of peripheral artery disease (PAD). Many basic researches and clinical treatment had been focused on stem cell transplantation for CLI. This systematic review was performed to review evidence for safety and efficacy of autologous stem cell therapy in CLI. Methods. A systematic literature search was performed in the SinoMed, PubMed, Embase, ClinicalTrials.gov, and Cochrane Controlled Trials Register databases from building database to January 2018. Results. Meta-analysis showed that cell therapy significantly increased the probability of ulcer healing (RR = 1.73, 95% CI = 1.45–2.06), angiogenesis (RR = 5.91, 95% CI = 2.49–14.02), and reduced the amputation rates (RR = 0.59, 95% CI = 0.46–0.76). Ankle-brachial index (ABI) (MD = 0.13, 95% CI = 0.11–0.15), TcO2 (MD = 12.22, 95% CI = 5.03–19.41), and pain-free walking distance (MD = 144.84, 95% CI = 53.03–236.66) were significantly better in the cell therapy group than in the control group (). Conclusions. The results of this meta-analysis indicate that autologous stem cell therapy is safe and effective in CLI. However, higher quality and larger RCTs are required for further investigation to support clinical application of stem cell transplantation.- 24 May 2018
- Published by Wiley in Stem Cells International
- Vol. 2018, 1-12
Open AccessAutologous Stem Cell Therapy in Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials
Objective. Critical limb ischemia (CLI) is the most dangerous stage of peripheral artery disease (PAD). Many basic researches and clinical treatment had been focused on stem cell transplantation for CLI. This systematic review was performed to review evidence for safety and efficacy of autologous stem cell therapy in CLI. Methods. A systematic literature search was performed in the SinoMed, PubMed, Embase, ClinicalTrials.gov, and Cochrane Controlled Trials Register databases from building database to January 2018. Results. Meta-analysis showed that cell therapy significantly increased the probability of ulcer healing (RR = 1.73, 95% CI = 1.45–2.06), angiogenesis (RR = 5.91, 95% CI = 2.49–14.02), and reduced the amputation rates (RR = 0.59, 95% CI = 0.46–0.76). Ankle-brachial index (ABI) (MD = 0.13, 95% CI = 0.11–0.15), TcO2 (MD = 12.22, 95% CI = 5.03–19.41), and pain-free walking distance (MD = 144.84, 95% CI = 53.03–236.66) were significantly better in the cell therapy group than in the control group (). Conclusions. The results of this meta-analysis indicate that autologous stem cell therapy is safe and effective in CLI. However, higher quality and larger RCTs are required for further investigation to support clinical application of stem cell transplantation.